A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.
Khalladi N, Dejean C, Bosset M, Pointreau Y, Kinj R, Racadot S, Castelli J, Huguet F, Renard S, Guihard S, Tao Y, Rouvier JM, Johnson A, Bourhis J, Xu Shan S, Thariat J.
Khalladi N, et al. Among authors: bosset m.
Cancer Radiother. 2021 Dec;25(8):755-762. doi: 10.1016/j.canrad.2021.04.005. Epub 2021 Sep 23.
Cancer Radiother. 2021.
PMID: 34565664
Clinical Trial.